Advanced search
1 file | 229.28 KB Add to list

Bupivacaine inhibits thromboxane A₂-induced vasoconstriction in rat thoracic aorta

(2004) ANESTHESIA AND ANALGESIA. 99(1). p.97-102
Author
Organization
Abstract
Plasma levels of thromboxane A(2) (TXA(2)), an inflammatory mediator inducing platelet aggregation, bronchoconstriction, and vasoconstriction, are increased in the perioperative period. A major role in the pathogenesis of perioperative thromboembolic and ischemic syndromes is attributed to this prostanoid. Local anesthetics (LA) inhibit signaling of TXA(2) receptors expressed in cell models. Therefore, we hypothesized that LA may inhibit vasoconstriction induced by the TXA(2) analog U46619 in rat thoracic aorta. Rings (3-mm length) of the rat thoracic aorta were mounted in organ baths and isometric contractile force was measured. Rings, with or without endothelium, were incubated for 60 min in bupivacaine (10(-6) or 10(-5) M) or Krebs-Henseleit solution (control group) and subsequently exposed to cumulative concentrations of U46619 (10(-10) to 10(-6) M). The reversibility of the TXA(2)-induced vasoconstriction by bupivacaine was also studied. Pretreatment of rings with bupivacaine concentration-dependently diminished TXA(2)-induced contraction in rat aortic rings. We found no significant differences in relaxing effect of bupivacaine between rings with and without endothelium. Contraction in rings established with U46619 could not be reversed by cumulative concentrations of bupivacaine. Bupivacaine inhibited carbachol-induced vascular relaxation. This study provides experimental evidence that bupivacaine is an endothelium-independent inhibitor of TXA(2)-induced vasoconstriction of rat thoracic aorta.
Keywords
ACTIVATION, IN VIVO, ROPIVACAINE, MICROCIRCULATION, RELEASE, RECEPTOR, LIDOCAINE, LOCAL-ANESTHETICS, PROSTACYCLIN

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 229.28 KB

Citation

Please use this url to cite or link to this publication:

MLA
Hahnenkamp, Klaus, JOKE NOLLET, Danja Strümper, et al. “Bupivacaine Inhibits Thromboxane A₂-induced Vasoconstriction in Rat Thoracic Aorta.” ANESTHESIA AND ANALGESIA 99.1 (2004): 97–102. Print.
APA
Hahnenkamp, K., NOLLET, J., Strümper, D., Halene, T., Rathman, P., Mortier, E., Van Aken, H., et al. (2004). Bupivacaine inhibits thromboxane A₂-induced vasoconstriction in rat thoracic aorta. ANESTHESIA AND ANALGESIA, 99(1), 97–102.
Chicago author-date
Hahnenkamp, Klaus, JOKE NOLLET, Danja Strümper, Tobias Halene, Pia Rathman, Eric Mortier, Hugo Van Aken, Joerg Knapp, Marcel E Durieux, and Christian W Hoenemann. 2004. “Bupivacaine Inhibits Thromboxane A₂-induced Vasoconstriction in Rat Thoracic Aorta.” Anesthesia and Analgesia 99 (1): 97–102.
Chicago author-date (all authors)
Hahnenkamp, Klaus, JOKE NOLLET, Danja Strümper, Tobias Halene, Pia Rathman, Eric Mortier, Hugo Van Aken, Joerg Knapp, Marcel E Durieux, and Christian W Hoenemann. 2004. “Bupivacaine Inhibits Thromboxane A₂-induced Vasoconstriction in Rat Thoracic Aorta.” Anesthesia and Analgesia 99 (1): 97–102.
Vancouver
1.
Hahnenkamp K, NOLLET J, Strümper D, Halene T, Rathman P, Mortier E, et al. Bupivacaine inhibits thromboxane A₂-induced vasoconstriction in rat thoracic aorta. ANESTHESIA AND ANALGESIA. 2004;99(1):97–102.
IEEE
[1]
K. Hahnenkamp et al., “Bupivacaine inhibits thromboxane A₂-induced vasoconstriction in rat thoracic aorta,” ANESTHESIA AND ANALGESIA, vol. 99, no. 1, pp. 97–102, 2004.
@article{310216,
  abstract     = {Plasma levels of thromboxane A(2) (TXA(2)), an inflammatory mediator inducing platelet aggregation, bronchoconstriction, and vasoconstriction, are increased in the perioperative period. A major role in the pathogenesis of perioperative thromboembolic and ischemic syndromes is attributed to this prostanoid. Local anesthetics (LA) inhibit signaling of TXA(2) receptors expressed in cell models. Therefore, we hypothesized that LA may inhibit vasoconstriction induced by the TXA(2) analog U46619 in rat thoracic aorta. Rings (3-mm length) of the rat thoracic aorta were mounted in organ baths and isometric contractile force was measured. Rings, with or without endothelium, were incubated for 60 min in bupivacaine (10(-6) or 10(-5) M) or Krebs-Henseleit solution (control group) and subsequently exposed to cumulative concentrations of U46619 (10(-10) to 10(-6) M). The reversibility of the TXA(2)-induced vasoconstriction by bupivacaine was also studied. Pretreatment of rings with bupivacaine concentration-dependently diminished TXA(2)-induced contraction in rat aortic rings. We found no significant differences in relaxing effect of bupivacaine between rings with and without endothelium. Contraction in rings established with U46619 could not be reversed by cumulative concentrations of bupivacaine. Bupivacaine inhibited carbachol-induced vascular relaxation. This study provides experimental evidence that bupivacaine is an endothelium-independent inhibitor of TXA(2)-induced vasoconstriction of rat thoracic aorta.},
  author       = {Hahnenkamp, Klaus and NOLLET, JOKE and Strümper, Danja and Halene, Tobias and Rathman, Pia and Mortier, Eric and Van Aken, Hugo and Knapp, Joerg and Durieux, Marcel E and Hoenemann, Christian W},
  issn         = {0003-2999},
  journal      = {ANESTHESIA AND ANALGESIA},
  keywords     = {ACTIVATION,IN VIVO,ROPIVACAINE,MICROCIRCULATION,RELEASE,RECEPTOR,LIDOCAINE,LOCAL-ANESTHETICS,PROSTACYCLIN},
  language     = {eng},
  number       = {1},
  pages        = {97--102},
  title        = {Bupivacaine inhibits thromboxane A₂-induced vasoconstriction in rat thoracic aorta},
  url          = {http://dx.doi.org/10.1213/01.ANE.0000118107.62304.25},
  volume       = {99},
  year         = {2004},
}

Altmetric
View in Altmetric
Web of Science
Times cited: